Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine

Published on April 16, 2021

The current data highlight the risk of serious thrombotic events in COVID-19, and can help contextualize and inform debate about the risk-benefit ratio for current COVID-19 vaccines. University of Oxford

Other news

Africa CDC Statement to Member States regarding thromboembolic events after vaccination with Janssen COVID-19 vaccine (Johnson & Johnson)

April 16, 2021
The Janssen COVID-19 vaccine is presently only use in South Africa, of all 55 member states.The Janssen COVID-19 vaccine was registered by the South African Health Products Regulatory Authority (SAHPRA) on April 6th and almost 290,000 doses had been administered. On 13th April 2021, the South Africa Minister of Health announced that the country had not registered any reports of blood clots and thr

2020 TEPHINET Annual Report

April 19, 2021
2020 TEPHINET Annual Report is now available.Learn how TEPHINET tackled the challenges presented by COVID-19 and worked to strengthen public health systems to better prepare the world for the next pandemic.